ReviewMicroorganisms2025
Alteration of Gut Microbiota by Ketogenic Diet as an Alternative Therapeutic Target for Drug-Resistant Epilepsy.
Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Plasma metabolomic signatures in children with autism spectrum disorder and their modulation following a gluten-free modified ketogenic diet.BMC psychiatry · 2026Article
- Aging, the microbiota-gut-brain axis, and late-life epilepsy: a hypothesis-driven review.Frontiers in molecular neuroscience · 2026Review
- Modulation of Gut Microbiome and Metabolome as One of the Potential Mechanisms of Ketogenic Diet Effect in the Treatment of Epilepsy.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
As one of the most serious and widespread neurological disorders, epilepsy affects nearly 70 million people worldwide. In the development of this disease, significant alterations of gut microbiotas are often observed in the patients. During the treatment of drug-resistant epilepsy, which accounts for ~20-30% of cases, a ketogenic diet (KD), a diet containing high fat, adequate protein, and low carbohydrate, has been widely used and showed promising therapeutic effects. The underlying mechanisms of the neuroprotective effects of a KD have been suggested in recent studies to be connected to the gut microbiota, the composition of which is dramatically influenced by this treatment. In this review, we summarize the recent advances of the relationship between a KD, gut microbiota, and epilepsy, with an emphasis on the gut bacterial changes under KD treatment, hoping to delineate the gut microbiota as a potential therapeutic target in epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.